Senior Management Team
Amit D. Munshi
Amit D. Munshi has served as a member of our Board of Directors since June 2016, and as our President and Chief Executive Officer since May 2016. Previously, Mr. Munshi served as President and Chief Executive Officer and a director of Epirus Biopharmaceuticals, Inc. from May 2012 to May 2016. Prior to Epirus, Mr. Munshi served as Chief Executive Officer of Percivia LLC, a biotechnology company, from 2011 to 2012, was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., from 2005 to 2010, and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker Graduate School of Management at Claremont Graduate University. Mr. Munshi has more than 25 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Mr. Munshi currently serves on the boards of Cytrellis Biosystems, Inc. and Pulmatrix, Inc. (NASDAQ: PULM).
Vince Aurentz has served as our Executive Vice President and Chief Business Officer since August 2016. Mr. Aurentz has over 28 years of experience in the biopharmaceutical industry. Previously, he served as the Chief Business Officer of Epirus Biopharmaceuticals. Prior to that, Mr. Aurentz served as President of HemoShear Therapeutics, where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children’s National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture). Mr. Aurentz received a B.S. in Mathematics from Villanova University.
Douglas A. Bakan, Ph.D.
Dr. Douglas A. Bakan has served as our Executive Vice President of Technical Operations since May 2018. Previously, Dr. Bakan served as Senior Vice President of Technical Operations from January 2017 to May 2018. He has extensive expertise in all aspects of pharmaceutical drug development and commercialization along with over 25-years of experience in firms ranging in size from entrepreneurial startups to established publicly traded companies. In various roles at companies including Medicis Pharmaceuticals (now Valeant Pharmaceuticals), Novalar Pharmaceuticals, Neurocrine Biosciences, Alerion Biomedical, MetaProbe LLC, Corvas International and Molecular Biosystems, Inc., Dr. Bakan has been responsible for activities including discovery research, nonclinical and clinical testing, CMC efforts for drug substance and drug product supply, quality system development, program management, regulatory submission preparation and review, intellectual property creation and prosecution, venture capital financing, technology in-licensing and out-licensing, and technical due diligence. Most recently, Dr. Bakan has provided pharmaceutical consulting services to various clients in the areas of product development, regulatory dossier preparation and technical due diligence. Dr. Bakan has been an author on more than 50 scientific publications and is an inventor on more than 35 issued or pending patents. Dr. Bakan earned his BS in Biomedical Engineering at UC San Diego, his Ph.D. in Biology from UC San Diego and completed post-doctoral research at the University of Michigan in the laboratories of Drs. Raymond Counsell and Jamey Weichert.
Chris Cabell, M.D., M.H.S. FACC
Dr. Chris Cabell, M.D., has served as our Senior Vice President and Head of Clinical Development since October 2017. Prior to joining Arena, Dr. Cabell spent 10 years at Quintiles Inc and QuintilesIMS in a variety of management positions including Chief Medical and Scientific Officer, Global Head of Medical and Project Management, and Global Head of Business Development. Prior to joining Quintiles, Dr. Cabell was on staff at Duke University, where he led efforts to begin two important collaborative consortia. In 1999, the International Collaboration on Endocarditis was formed and Dr. Cabell received National Institutes of Health (NIH) funding to support the novel effort to study a disease of low prevalence, but high morbidity and mortality. In addition, Dr. Cabell was one of the founding members and Co-Chairs for the Cardiac Safety Research Consortium, a partnership between academic medical centers, the Food and Drug Administration (FDA), and Industry. He is also a Fellow of the American College of Cardiology. Dr. Cabell has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is a graduate of Pennsylvania State University and Duke University, earning both his medical degree and a Masters in Health Sciences from the latter.
Preston Klassen, M.D., M.H.S.
Dr. Klassen has over 20 years of experience in biopharmaceutical product development. Most recently, he was Chief Medical Officer of Laboratoris Sanifit S.L. and prior to that was Executive Vice President, Head of Global Development at Orexigen Therapeutics, Inc. Previously, Dr. Klassen held several positions of increasing responsibility at Amgen Inc., including Therapeutic Area Head for Nephrology. Prior to joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center. Dr. Klassen received his medical degree from the University of Nebraska College of Medicine and completed his residency in internal medicine, fellowship in nephrology, and masters in health sciences degree at Duke University.
Kevin R. Lind
Kevin R. Lind has served as our Executive Vice President and Chief Financial Officer since June 2016. Previously, Mr. Lind was a Principal focused on healthcare at TPG Special Situations Partners, a global investment firm, from January 2009 to June 2016. Mr. Lind was a member of the TPG Pharma Partners effort at TPG-Axon, a global investment firm, from 2006 to 2008. He served in various capacities as a healthcare investment banker at Lehman Brothers, Inc., a former global financial services firm, from 1998 to 2002 and 2004 to 2006. Mr. Lind received a B.S. from Stanford University in Biological Sciences and an M.B.A. from UCLA Anderson School of Management.
Cate Scanlon has served as our Vice President, Global Human Resources since October 2016. Cate has over 15 years of diverse human resources experience from early-stage to Fortune 500 companies with an emphasis on the entrepreneurial biotechnology sector. Most recently she was Vice President of Human Resources at Verenium Corporation (now part of BASF) where she was a member of the Executive Leadership Team and led all the strategic and operational HR efforts with regards to Total Rewards, Talent Development and organizational development. Prior to Verenium, from 2001 to 2007 she held various roles at Cambridge Energy Research Associates, a global retainer research firm specializing in the energy sector and based in Cambridge, MA. Cate has a Bachelor’s Degree in English from Canisius College, Buffalo, NY and a Master’s Degree in Counseling Psychology from Boston College, Chestnut Hill, MA. She also holds certifications from World at Work (Certified Compensation Professional), Society for Human Resources, Senior Professional in Human Resources (SPHR) and Institute for the Future, Foresight Practitioner.
Steven W. Spector, J.D.
Steven W. Spector, J.D., has served as our Executive Vice President and General Counsel since February 2012. Mr. Spector served as our Senior Vice President and General Counsel from June 2004 to February 2012, and as our Vice President and General Counsel from October 2001 to June 2004. Mr. Spector has also served as our Secretary since November 2001. Mr. Spector is a member of the board of directors and a former President of the Association of Corporate Counsel, San Diego, and an Adjunct Professor at the University of San Diego School of Law. Prior to joining Arena, Mr. Spector was a partner with the law firm of Morgan, Lewis & Bockius LLP, where he worked from 1991 to October 2001. Mr. Spector holds a B.A. and a J.D. from the University of Pennsylvania.